Literature DB >> 19870942

A CRYSTALLINE PRESSOR SUBSTANCE (ANGIOTONIN) RESULTING FROM THE REACTION BETWEEN RENIN AND RENIN-ACTIVATOR.

I H Page1, O M Helmer.   

Abstract

1. Renin reacts with renin-activator to form a strong pressor substance which is heat-stable, water- and alcohol-soluble, fluorescent, acid-stable, and alkali-labile. It is a reducing substance and is destroyed by strong oxidizing substances. It forms crystalline salts with oxalic and picric acids. The color reaction for arginine is the only one found to be strongly positive. It is suggested that this substance be called angiotonin. 2. Angiotonin produces a sharp, immediate rise in arterial pressure when injected intravenously. Pithing and dissipation of the anesthetic appear to increase the response. Tachyphylaxis occurs, in contrast to renin, only after many single doses. 3. The responses to adrenaline and angiotonin do not parallel one another. Cocaine, atropine, and stilbestrol do not affect the pressor action of angiotonin. Suprarenalectomy in brief experiments is also without effect. 4. Maximal amounts of angiotonin result when the proportion between renin and activator is roughly 3 to 100. This is not a stoichiometric relationship in the chemical sense. The temperature suitable for good yields is about 38 degrees C., and the time of reaction from 10 to 20 minutes. 5. Renin destroys angiotonin when incubated with it. 6. Angiotonin causes marked contraction of intestinal segments of rabbits without reducing their rhythmic motion. It sensitizes the intestine to further doses of angiotonin and alters the intestine such that renin-activator contracts it. Angiotonin also constricts the vessels of a rabbit's ear perfused with blood or Ringer's solution.

Entities:  

Year:  1940        PMID: 19870942      PMCID: PMC2134997          DOI: 10.1084/jem.71.1.29

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  1 in total

1.  ON THE NATURE OF THE PRESSOR ACTION OF RENIN.

Authors:  I H Page
Journal:  J Exp Med       Date:  1939-10-31       Impact factor: 14.307

  1 in total
  48 in total

Review 1.  HOPE gives reason for hope. Heart Outcomes Prevention Evaluation.

Authors:  E L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2000-02       Impact factor: 5.369

Review 2.  The discovery of a novel macrophage binding site.

Authors:  Juan M Saavedra; Jaroslav Pavel
Journal:  Cell Mol Neurobiol       Date:  2006-04-22       Impact factor: 5.046

Review 3.  Historical perspective of the renin-angiotensin system.

Authors:  John E Hall
Journal:  Mol Biotechnol       Date:  2003-05       Impact factor: 2.695

4.  [Renin and hypertension, physiological or pathological agents?].

Authors:  F GROSS
Journal:  Klin Wochenschr       Date:  1958-08-01

5.  [Effect of synthetic hypertensin II on PAH- and inulin clearance, on renal hemodynamics and on diuresis in man].

Authors:  H D BOCK; H J KRECKE
Journal:  Klin Wochenschr       Date:  1958-01-15

Review 6.  The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.

Authors:  John W Wright; Joseph W Harding
Journal:  Pflugers Arch       Date:  2012-04-26       Impact factor: 3.657

7.  Pharmacological characterization of angiotensin II AT(2) receptor subtype heterogeneity in the rat adrenal cortex and medulla.

Authors:  X Lu; K L Grove; W Zhang; R C Speth
Journal:  Endocrine       Date:  1995-04       Impact factor: 3.633

8.  Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease.

Authors:  Jose L Labandeira-Garcia; Jannette Rodriguez-Pallares; Ana I Rodríguez-Perez; Pablo Garrido-Gil; Begoña Villar-Cheda; Rita Valenzuela; Maria J Guerra
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

Review 9.  Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities.

Authors:  Juan M Saavedra
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

Review 10.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.